This project aims to support the delivery of Clinical Fellow-led amyloidosis services through a collaborative working agreement between Manchester University NHS Foundation Trust and Pfizer. The service will be overseen by two consultant cardiologists and the Multi-Disciplinary Team (MDT). This project is designed to ensure a thorough and coordinated clinical pathway for patients with suspected or confirmed CA, enabling access to local MDT input and specialist diagnostics. It also ensures timely access to licensed treatments and appropriate follow-up care.

• Improved access to specialised diagnostics, medicines and licensed treatments.
• Healthcare support at a local level.
• Continuity of care from tertiary hospital to District General Hospital.
• Reduction of unnecessary hospital visits.
• Improved equity of access (e.g. lower cost barriers to access care in community settings).
• Improved adherence to licensed treatments through new models of care.
• Supporting better outcomes for amyloid patients (e.g., improve decision making at specialist MDT, access to expert diagnostics, direct links to NAC).
• More appropriate cases discussed, thus timely case review leading to improved patient access to MDT, specialist services and diagnostics minimising waiting times.
• Reduced variation between trusts across the region and improving equity for patients.

• Improved pathways that utilise the capacity and specialised clinical competencies for rare cardiomyopathy disease to support the NHS in addressing issues of rare CA.
• Efficiency in Manchester Amyloidosis Service (MAS) working practice.
• Maintain or improve the time from referral to diagnosis.
• Clinical care aligned with standards of care developed by the NAC.
• Enabling areas to be identified for improvement to enhance best practice.
• Data collection in line with interventions of Rare Disease Framework and England Action Plan 2022.

• Understanding new patient pathways for accessing hospital only medicines in the community.
• Understanding which channels to distribute our medicines through to get them to patients in a safe, robust, and convenient way.
• Increase number of patients diagnosed and treated.
• Increase access to licensed Pfizer medicines in appropriate patients.
• Improve the understanding of more challenging to reach populations.

• Local pathway established for patients with suspicion/confirmed of cardiac amyloidosis.
• Follow-up service established for patients living further away from the centre.
• Improved patient management and continuity of care.
• Reduced health inequities in this therapy area.

• Funding:
  • Clinical Fellow: £150,000.00
• Human resource: 270 hours (£12,150.00)
• Total transfer of value: £162,150.00*

*This is calculated as the sum of the direct financial contribution by Pfizer PLUS the benefit in kind value of the human resources provided by Pfizer

• Diagnostics: £148,580.00
• Human resource: 1,273 hours (£57,285.00)
• Total: £205,865.00